Central Venous Pressure Guided Hydration Prevention for Contrast-Induced Nephropathy

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 264 participants.

Also called NCT02405377

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose prevention
Phase
Not applicable
Enrolled
  • 264 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02405377
Other papers using this trial's data
  • Prevention of Contrast-Induced Nephropathy by Central Venous Pressure-Guided Fluid Administration in Chronic Kidney Disease and Congestive Heart Failure Patients JACC. Cardiovascular interventions, 2016-01-11 DOI, PubMed 26685074

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02405377. Randomized; triple masking; primary purpose prevention. Start 2014-02 (registry gives no type); primary completion 2015-02 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Central Venous Pressure Guided Hydration Prevention for Contrast-Induced Nephropathy
Condition
Cardio-Renal Syndrome
Intervention (Procedure)
hydration
Intervention (Drug)
Visipaque
Intervention (Drug)
0.9% sodium chloride fluid administration
Intervention (Device)
5-French catheter
Lead sponsor
Chinese PLA General Hospital (class: other)

Record details

Record id
cardio:ct-nct02405377
Content hash
16ae1a2389850fb9cd48fd79a56cdc7931adf1b78f40d0d24a0004a070b3e08d